- Home
- KRC vs BLTE Comparison
KRC vs BLTE Comparison
Compare KRC & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRC | BLTE |
|---|---|---|
| Founded | 1947 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.1B |
| IPO Year | 1997 | 2022 |
Fundamental Metrics
Financial Performance| Metric | KRC | BLTE |
|---|---|---|
| Price | $40.44 | $149.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 6 |
| Target Price | $41.58 | ★ $149.00 |
| AVG Volume (30 Days) | ★ 1.2M | 246.7K |
| Earning Date | 10-27-2025 | 11-10-2025 |
| Dividend Yield | ★ 5.34% | N/A |
| EPS Growth | ★ 62.23 | N/A |
| EPS | ★ 2.71 | N/A |
| Revenue | ★ $1,126,859,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.41 | N/A |
| P/E Ratio | $14.92 | ★ N/A |
| Revenue Growth | ★ 0.77 | N/A |
| 52 Week Low | $27.07 | $49.00 |
| 52 Week High | $45.03 | $160.55 |
Technical Indicators
Market Signals| Indicator | KRC | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 40.31 | 69.65 |
| Support Level | $40.10 | $140.07 |
| Resistance Level | $41.56 | $160.55 |
| Average True Range (ATR) | 1.14 | 12.76 |
| MACD | -0.18 | 1.29 |
| Stochastic Oscillator | 15.46 | 80.13 |
Price Performance
Historical ComparisonAbout KRC Kilroy Realty Corporation
Kilroy Realty is a premier owner and landlord of approximately 17 million square feet of office space across Los Angeles, San Diego, the San Francisco Bay Area, Austin, Texas, and greater Seattle. The company operates as a real estate investment trust.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.